Akari Therapeutics (NASDAQ:AKTX) received FDA orphan drug designation for nomacopan for the treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA) in pediatric patients. HSCT...
By Len Zehr Closely held Gamida Cell has shifted its focus to its second-generation stem cell product, NiCord, for the treatment of hematological malignancies and non-malignant hematological diseases in the wake of an...
By Len Zehr Positive animal data reported by International Stem Cell (OTCBB:ISCO) last month brings the company one step closer to starting human testing of its stem cell technology to treat Parkinson’s disease. “We...